Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897765 · ClinicalTrials.gov registry record · Phase 1
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
A Phase 1 study, sponsored by BioNTech US.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02897765 is a Phase 1 study that has completed, run by BioNTech US. The registered enrollment target is 34 participants.
The verdict
NCT02897765, a Phase 1 study, has completed, sponsored by BioNTech US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL NEO-PV-01
- OTHER Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02897765
The ClinicalTrials.gov registry entry for NCT02897765 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech US, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02897765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02897765 about?
NCT02897765 is a clinical study titled "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer". The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other av...
What is the current status of trial NCT02897765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-10. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02897765?
The interventions under investigation include: Nivolumab (BIOLOGICAL), NEO-PV-01 (BIOLOGICAL), Adjuvant (OTHER).
Who is sponsoring clinical trial NCT02897765?
This trial is sponsored by BioNTech US, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.